{"id":61667,"date":"2026-03-28T21:07:14","date_gmt":"2026-03-28T13:07:14","guid":{"rendered":"https:\/\/flcube.com\/?p=61667"},"modified":"2026-03-28T21:07:15","modified_gmt":"2026-03-28T13:07:15","slug":"fda-approves-rocket-pharmas-kresladi-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-type-i","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61667","title":{"rendered":"FDA Approves Rocket Pharma’s Kresladi \u2013 First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I"},"content":{"rendered":"\n

The U.S. Food and Drug Administration (FDA)<\/strong> this week approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel)<\/strong>, the first gene therapy<\/strong> for the treatment of severe type I leukocyte adhesion deficiency (LAD-I)<\/strong>. The autologous hematopoietic stem cell gene therapy<\/strong> addresses the underlying genetic cause<\/strong> of this ultra-rare, life-threatening pediatric immunodeficiency<\/strong>, offering a potentially curative alternative<\/strong> to high-risk allogeneic stem cell transplantation.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Approval Type<\/strong><\/td>First gene therapy for LAD-I<\/td><\/tr>
Product<\/strong><\/td>Kresladi (marnetegragene autotemcel)<\/td><\/tr>
Developer<\/strong><\/td>Rocket Pharmaceuticals (local U.S. firm)<\/td><\/tr>
Indication<\/strong><\/td>Severe leukocyte adhesion deficiency type I (LAD-I)<\/td><\/tr>
Approval Significance<\/strong><\/td>First and only approved therapy<\/strong> for severe LAD-I<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>Severe LAD-I Profile<\/th><\/tr><\/thead>
Genetic Basis<\/strong><\/td>Autosomal recessive<\/strong> mutations in ITGB2 gene<\/strong><\/td><\/tr>
Pathophysiology<\/strong><\/td>Defective CD18\/CD11a integrin expression<\/strong> \u2013 white blood cells unable to migrate to infection sites<\/td><\/tr>
Clinical Manifestation<\/strong><\/td>Recurrent, life-threatening bacterial\/fungal infections<\/strong>; poor wound healing; delayed umbilical cord separation<\/td><\/tr>
Prognosis<\/strong><\/td>High morbidity\/mortality within first decade<\/strong> without curative intervention<\/td><\/tr>
Current Standard<\/strong><\/td>Allogeneic hematopoietic stem cell transplantation<\/strong> \u2013 high morbidity\/mortality risk, especially without HLA-matched sibling donor<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Kresladi Mechanism & Administration<\/h2>\n\n\n\n
Attribute<\/th>Kresladi Specification<\/th><\/tr><\/thead>
Format<\/strong><\/td>Autologous gene therapy<\/strong> \u2013 patient-derived hematopoietic stem cells (HSCs)<\/td><\/tr>
Genetic Modification<\/strong><\/td>Functional ITGB2 gene<\/strong> introduced via lentiviral vector<\/td><\/tr>
Mechanism<\/strong><\/td>Restores CD18 and CD11a protein expression<\/strong> on neutrophils and other leukocytes<\/td><\/tr>
Administration<\/strong><\/td>Single intravenous dose<\/strong> following myeloablative conditioning<\/td><\/tr>
Therapeutic Goal<\/strong><\/td>Functional cure<\/strong> \u2013 restoration of immune cell trafficking and infection defense<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Ultra-Rare Prevalence<\/strong><\/td>~1\u20132 cases per million births<\/strong>; ~50\u2013100 severe cases<\/strong> in U.S.; ~500\u20131,000 globally<\/strong> \u2013 orphan pricing justified<\/td><\/tr>
Gene Therapy Pricing Paradigm<\/strong><\/td>Expected $2\u20133 million one-time therapy<\/strong> \u2013 cost-effective vs. chronic infections, hospitalizations, and transplant risks<\/td><\/tr>
Rocket Pharma Pipeline<\/strong><\/td>Kresladi anchors hematopoietic stem cell gene therapy platform<\/strong>; additional programs in Fanconi anemia, pyruvate kinase deficiency<\/td><\/tr>
Manufacturing Scale<\/strong><\/td>In-house lentiviral vector and cell processing capabilities<\/strong>; capacity for 20\u201330 patients annually<\/strong> initially<\/td><\/tr>
Competitive Landscape<\/strong><\/td>First-mover advantage<\/strong> \u2013 no other LAD-I gene therapies in clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n